Comprehensive analysis of the clinical and biological significances for chemokine CXCL3 in cholangiocarcinoma

Hongyue Ren,Xiaofan Yang,Wenrong Hou,Jiarong Meng,Deqing Luo,Chunbin Zhang
DOI: https://doi.org/10.1097/md.0000000000037460
IF: 1.6
2024-03-17
Medicine
Abstract:Cholangiocarcinoma (CHOL) is rare but aggressive tumor, which can emerge at any point of the biliary tree. Due to the different anatomical locations, CHOL can be divided into 3 subtypes: intrahepatic CHOL, periportal CHOL and distal CHOL. [ 1 ] In the world wide, the incidence and mortality rates of CHOL are constantly increasing with an incidence rate of 0.3 to 6/100,000 and a mortality rate of 1 to 6/100,000 inhabitants per year. [ 2 ] Due to the silent clinical course, lack of biomarkers, hidden anatomical location, and highly desmoplastic and paucicellular nature, CHOL is known as insidious onset and difficult treatment. [ 3 ] Early CHOL is mostly asymptomatic, resulting in a high detection rate of diagnosis at an advanced stage. Surgical resection is the main curative option for CHOL, but it is no longer feasible for advanced patients. [ 4 ] Other systemic therapies, traditional chemotherapy and target therapies are currently available choices for unresectable CHOL patients, but effective treatment biomarkers have not yet been identified. [ 3 ] Consequently, CHOL patients have very poor prognosis with a 5-year overall survival of <10%. [ 5 ] As such, it is necessary to identify novel and reliable biomarkers that can be employed in the clinical screening, diagnosis, treatment and prognosis of CHOL patients.
medicine, general & internal
What problem does this paper attempt to address?